SCHEMBL7765096

SCHEMBL7765096

C=CCC(NC(=O)C(CCCc1ccc(-c2ccccc2)cc1)CC(=O)O)C(=O)Nc1ccc(C(=O)OC)cc1

nearest known ligand 0.53

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 19/20 0.53
MMP3 P08254 10/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9289897 0.88 MMP3 (0.58) MMP2MMP3
SCHEMBL7758445 0.85 MMP2 (0.52) MMP2MMP3
SCHEMBL7763165 0.83 MMP3 (0.56) MMP2MMP3
SCHEMBL7763668 0.81 MMP3 (0.54) MMP2MMP3
SCHEMBL7762285 0.80 MMP2 (0.82) MMP2MMP3
SCHEMBL7758535 0.80 MMP3 (0.59) MMP2MMP3
SCHEMBL7764977 0.80 MMP3 (0.59) MMP2MMP3
SCHEMBL7762087 0.79 MMP3 (0.52) MMP2MMP3
SCHEMBL7763782 0.78 MMP3 (0.51) MMP2MMP3
SCHEMBL7763812 0.78 MMP3 (0.54) MMP2MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1098662-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2001-05-16 EP claimed
WO-2000004892-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2000-02-03 WO claimed
EP-1098662-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2001-05-16 EP disclosed
WO-2000004892-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2000-02-03 WO disclosed